Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

6.12
-0.0750-1.21%
Volume:322.64K
Turnover:1.98M
Market Cap:420.28M
PE:-2.63
High:6.30
Open:6.12
Low:5.98
Close:6.19
Loading ...

EyePoint Pharmaceuticals Prices $140 Million Public Offering

MT Newswires Live
·
30 Oct 2024

Stock Track | EyePoint Stock Plunges Over 8% on $100M Stock Offering Despite Positive Trial Data

Stock Track
·
30 Oct 2024

BRIEF-Eyepoint Pharmaceuticals Prices Public Offering Of 12.7 Mln Shares At $11.00 Each

Reuters
·
30 Oct 2024

EyePoint Pharmaceuticals Inc - Prices Public Offering of 12.7 Mln Shares at $11.00 Each

THOMSON REUTERS
·
30 Oct 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

GlobeNewswire
·
30 Oct 2024

Stock Track | EyePoint Shares Plummet on $100M Stock Offering Despite Positive Trial Data

Stock Track
·
30 Oct 2024

Stock Track | EyePoint Surges Over 5% on Positive Duravyu Clinical Updates

Stock Track
·
29 Oct 2024

EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
29 Oct 2024

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

Zacks
·
29 Oct 2024

Stock Track | EyePoint Pharmaceuticals Plunges After $100M Stock Offering Overshadows Positive Trial Data

Stock Track
·
29 Oct 2024

Stock Track | EyePoint Shares Plunge After $100M Stock Offering Amid Positive Trial Data

Stock Track
·
29 Oct 2024

BUZZ-EyePoint slides after unveiling $100 mln stock offering

Reuters
·
29 Oct 2024

EyePoint announces $100M offering of common stock

TIPRANKS
·
29 Oct 2024

EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering

THOMSON REUTERS
·
29 Oct 2024

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
29 Oct 2024

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

Benzinga
·
29 Oct 2024